It is therapeutically desirable to effectively deliver ceramide, an antimitogenic and proapoptotic lipid second messenger, to transformed cell types. However, the targeted delivery of cellpermeable ceramide analogs, including C 6 -ceramide, to cells may be impeded by the hydrophobicity of these bioactive lipids, resulting in reduced efficacy. The objective of this study is to develop and optimize liposomal vehicles to augment ceramide delivery to a breast adenocarcinoma cell line. We designed conventional, cationic, and pegylated drug release vesicles to efficaciously deliver ceramide to MDA-MB-231 breast adenocarcinoma cells. In vitro pharmacokinetic analysis demonstrated that liposomal ceramide delivery resulted in significantly greater accumulation of ceramide in MDA-MB-231 cells. Ceramide-formulated liposomes significantly inhibited MDA-MB-231 cell proliferation as compared with nonliposomal administration of ceramide. Ceramide-induced apoptosis correlated with the pharmacokinetic profile and the diminished proliferation in this highly aggressive, metastatic cell line. Liposomal ceramide formulations inhibited phosphorylated Akt levels and stimulated caspase-3/7 activity more effectively than nonliposomal ceramide, events consistent with apoptosis. Together, these results indicate that bioactive ceramide analogs can be incorporated into conventional, cationic, or pegylated liposomal vehicles for improved drug delivery and release.
Sphingolipid metabolites are a unique class of lipids that have been shown to control the balance between mitogenesis and apoptosis. These lipids serve both a structural role in membranes and an intracellular signaling role within a cell. Ceramide is one of many sphingolipid metabolites known to have biological activity, serving as a lipid-derived second messenger that modulates the induction of cell differentiation, cell cycle arrest, and/or apoptosis (Hannun, 1994; Spiegel and Merrill, 1996; Merrill et al., 1997; Kolesnick and Kronke, 1998) . Intracellular ceramide accumulation results from multiple stimuli, such as growth factor deprivation (Ito and Horigome, 1995) , cytokines (Ballou et al., 1992; Dbaibo et al., 1993; Tepper et al., 1995) , chemotherapy and other cytotoxic agents (Strum et al., 1994; Bose et al., 1995; Lucci et al., 1999) , ionizing radiation (Haimovitz-Friedman et al., 1994; Bruno et al., 1998) , heat shock (Chang et al., 1995) , and various environmental factors (Hannun, 1996; Basu and Kolesnick, 1998) . These stimuli have been observed to initiate ceramide-mediated signaling cascades, including the inhibition of Akt prosurvival pathways and the stimulation of caspase activity, which ultimately leads to DNA fragmentation and cell death (Jarvis et al., 1994; Tepper et al., 1999) .
Due to its potent regulation of cell growth, differentiation, and death and the fact that it is a natural molecule that targets discrete kinases and signaling pathways linked to proliferation and/or survival, ceramide has been identified as a putative therapeutic agent in cancer (Radin, 2001 ) and cardiovascular disease (Johns et al., 1998) . Our laboratory has demonstrated the potential clinical utility of local delivery of a cell-permeable ceramide analog (C 6 ) from drug-eluting platforms. Specifically, ceramide-coated balloon catheters induced cell cycle arrest in stretch-injured vascular smooth muscle cells (Charles et al., 2000) . Although the delivery of C 6 from coated and distended balloons allows for direct delivery to the vasculature, there are several obstacles to the delivery of ceramide for systemic applications, such as cancer chemotherapy. Three significant barriers to systemic ceramide delivery exist. First, even though short-chain, cell-permeable ceramide analogs (C 2 -, C 6 -, or C 8 -ceramide) are more efficacious than physiological long-chain ceramides (C 18 -C 24 -ceramide), their effectiveness remains limited due to their hydrophobicity and possible precipitation as fine lipid micelle suspensions when administered in aqueous solutions (Radin, 2001) . Second, the existence of a second aliphatic chain, albeit a short-chain derivative, hinders cellular permeability. Finally, because ceramide is a natural cellular lipid, circulating levels of free ceramide is susceptible to enzymatic degradation by ceramide-specific enzymes, such as ceramidase. Thus, there is a critical need for improved delivery systems to maximize intracellular ceramide accumulation upon systemic administration. We hypothesize that the development and optimization of ceramide-formulated liposomal vehicles will augment ceramide delivery, translating to enhanced growth inhibition and/or apoptosis in cancer. To test this hypothesis, we compared the in vitro pharmacokinetics, efficacy, and intracellular bioactivity of liposomal and nonliposomal C 6 formulations in an in vitro model of human metastatic breast adenocarcinoma.
Materials and Methods
Materials and Cell Culture. Egg phosphatidylcholine (EPC), dioleoyl phosphatidylethanolamine (DOPE), dioleoyl phosphatidylcholine (DOPC), cholesterol (CH), D-erythro-hexanoyl-sphingosine (C 6 -ceramide), polyethyleneglycol-450-C 8 -ceramide (PEG-C8), and dioleoyl-1,2-diacyl-3-trimethylammonium-propane (DOTAP) were purchased from Avanti Polar Lipids (Alabaster, AL). Di-hydroerythro-hexanoyl-sphingosine (DHC 6 ) was purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA (Gibbstown, NJ). Formvar/carbon-coated 400 mesh copper grids were purchased from Electron Microscopy Sciences (Fort Washington, PA), and poly-L-lysine was obtained from Sigma-Aldrich (St. Louis, MO). Antibodies specific for phosphorylated Akt (pAkt) and Akt-1,2,3 were purchased from Cell Signaling Technology Inc. (Beverly, MA). Insulin-like growth factor-1 (IGF-1) was obtained from Calbiochem (San Diego, CA). For Western blotting, 4 to 12% precasted SDS-polyacrylamide gel electrophoresis gradient gels were obtained from Invitrogen (Carlsbad, CA), and enhanced chemiluminescence reagent was purchased from Amersham Biosciences Inc. (Piscataway, NJ). The TUNEL apoptosis detection kit was obtained from Upstate Biotechnology (Lake Placid, NY). The Vybrant apoptosis assay kit #3 was purchased from Molecular Probes (Eugene, OR), and the Apo-ONE homogeneous caspase-3/7 assay was obtained from Promega (Madison, WI). Rnase was purchased from Roche Diagnostics (Indianapolis, IN), and propidium iodide (PI) was obtained from Sigma-Aldrich. Human MDA-MB-231 (MDA) breast adenocarcinoma cells were obtained from American Type Culture Collection (Manassas, VA) and grown at 37°C in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). This cell line is a highly aggressive metastatic, estrogen receptor-negative model of human breast cancer.
Liposome Formulation and Extrusion. Lipids, dissolved in chloroform (CHCl 3 ), were combined in specific molar ratios, dried under a stream of nitrogen above lipid transition temperatures, and hydrated with sterile phosphate-buffered saline (PBS). The resulting solution underwent sonication for 2 min followed by extrusion through 100-nm polycarbonate membranes. Incorporation efficiency was determined by incorporating trace amounts of [
3 H]C 6 in the formulation, extracting constituent lipids in CHCl 3 /MeOH (2:1), and comparing radioactivity before and after extrusion using a scintillation counter. The composition of formulated liposomes was validated by extracting constituent lipids in CHCl 3 /MeOH (2:1), followed by resolution on preheated silica gel 60 thin layer chromatography plates using a CHCL 3 /MeOH/ddH 2 O (60:25:4) solvent system. Lipids were visualized in an iodine chamber.
Transmission Electron Microscopy (TEM). To characterize the size and morphology of the formulated liposomes, we utilized TEM. Initially, formvar carbon-coated 400 mesh copper grids were coated with poly-L-lysine for 10 min to promote vesicular binding to the hydrophobic grids. Liposomal samples were next applied to the dried grids and allowed to adhere for 5 min. Negative staining was performed by applying 1% phosphotungstic acid (pH 7.0) to the dried grid for an additional 5 min. The sample was observed at 21,500ϫ magnification with an accelerating voltage of 60 kV.
In Vitro Pharmacokinetics. MDA cells were seeded at 3. Caspase Assay. MDA cells were seeded to a density of 6.0 ϫ 10 3 cells/well in 96-well plates and grown for 48 h in culture media containing 10% FBS. Cells were then treated with liposomal or nonliposomal C 6 for 24 h in media containing 1% FBS. Caspase-3/7 enzymatic activity levels were measured using the Apo-ONE homogenous caspase-3/7 assay and performed following the instructions of the manufacturer. The kit provides a caspase-3/7 substrate and rhodamine 110, bis
, which is cleaved by enzymatically active caspase-3/7 resulting in a fluorogenic cleavage product. Apoptosis Detection. To determine DNA fragmentation, the TUNEL apoptosis detection kit was performed according to the instructions of the manufacturer. Briefly, MDA cells were seeded at a density of 1.0 ϫ 10 4 cells/well in eight-well chamber slides and grown for 48 h in culture media containing 10% FBS. Cells were then treated with liposomal or nonliposomal C 6 for 8 and 16 h in media supplemented with 1% FBS. Fragmented DNA of apoptotic cells was stained in situ using terminal deoxynucleotidyl transferase to transfer biotin-dUTP to the free 3Ј-OH end of cleaved DNA, which were visualized by reaction with FITC-avidin.
In addition to TUNEL, apoptosis was assessed and quantified by flow cytometry analysis of annexin V-stained cells using the Vybrant apoptosis assay kit according to the instructions of the manufacturer. Briefly, MDA cells were seeded at 1.0 ϫ 10 6 cells/plate in 100-mm tissue culture dishes and grown for 48 h in culture media containing 10% FBS. Cells were then treated with liposomal or Novel Drug Delivery Systems for Ceramide nonliposomal C 6 for 24 h in media supplemented with 1% FBS. Following treatment, adherent cells were harvested by trypsinization, and all cells (floating and adherent) were washed once with cold PBS. Pelleted cells were then stained with FITC-labeled annexin V and PI according to the instructions of the manufacturer. Labeled cells were immediately analyzed using flow cytometry. Viable cells were double negative, early apoptotic cells were positive for annexin V staining and negative for PI staining, and late apoptotic cells were double positive.
Apoptosis and DNA degradation was confirmed by performing cell cycle analysis of PI-stained cells. MDA cells were plated and treated similar to the annexin V experiment above. Following treatment, adherent cells were harvested by trypsinization, and all cells (floating and adherent) were washed once with cold PBS and fixed with 70% ethanol for 30 min. Fixed cells were pelleted and stained with a PI solution (50 g/ml PI, 0.1 mg/ml Rnase A, and 0.05% Triton X-100) for 40 min at 37°C in the dark and analyzed immediately using flow cytometry. Apoptotic cells were identified in the subdiploid (subG o /G 1 ) region. Cell debris was excluded from analysis using forward scatter/side scatter live gate.
Western Blot Analysis. MDA cells were seeded at 4.0 ϫ 10 5 cells/well in 60-mm plates and grown overnight prior to 24-h serum starvation. At h 16 of serum starvation, cells were treated with liposomal or nonliposomal C 6 for the remainder of serum starvation. At h 24 of serum starvation, IGF-1 (20 ng/ml) was added to cell media for a 15-min period. Cells were washed once with cold PBS followed by the addition of 150 l of cold lysis buffer (1% Triton X-100, 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM Na 4 P 2 O 7 , 1 mM ␤-glycerolphosphate, 1 mM Na 3 VO 4 , and 1 g/ml leupeptin in ddH 2 O, pH 7.5) on ice. Cells were lysed for 15 min on ice, and cell lysate was harvested and centrifuged at 15,000g for 15 min. Thirtyfive micrograms of protein were loaded in 4 to 12% precasted SDSpolyacrylamide gel electrophoresis gradient gels and probed for pAkt. Blots were stripped and reprobed for Akt-1,2,3 to demonstrate equal loading. Protein bands were visualized using enhanced chemiluminescence and quantified by densitometry. Statistical Analysis. Differences among treatment groups were statistically analyzed using a two-tailed Student's t test for statistical analyses. A statistically significant difference was reported if p Ͻ 0.05 or less. Data are reported at the mean Ϯ S.E. from at least n ϭ 3 separate experiments.
Results
Liposome Formulations and Characterization. Lipids were formulated and tested for their ability to incorporate C 6 into liposomal drug delivery vesicles. The calculation for C 6 concentration was determined from the specific molar ratio of C 6 in each formulation, which always comprised 10 mg/ml of total lipid. "Conventional" liposomal formulations, suitable for the delivery of proteins and therapeutic agents, were initially validated as to size, composition, and ceramide incorporation. In addition, we characterized "cationic" liposomes, effective for the delivery of negatively charged oligonucleotides, as well as "pegylated" liposomes, which have the potential to improve the hydrophilicity and bioavailability of drug-releasing liposomes by evading the reticular endothelial system (Reddy, 2000) . TEM analysis confirmed that C 6 -incorporated liposomal vehicles were produced with a homogenous size distribution between 85 and 140 nm in diameter for all formulations (Fig. 1A) . With the incorporation of trace amounts of [
3 H]C 6 into conventional formulations, we observed that there was no significant loss of ceramide during the extrusion process (Fig. 1B) . Additionally, lipid extracts from conventional liposomes were run on thin layer chromatography plates, confirming that there was no visual diminution of lipid constituents during the extrusion process (Fig.  1C) .
In Vitro Pharmacokinetics. We incorporated trace amounts of [
3 H]C 6 into liposomal formulations to quantify the amount of C 6 liposomal delivery compared with nonliposomal administration. In vitro pharmacokinetic studies showed that liposomal formulations delivered C 6 more effectively and efficiently than nonliposomal administration of C 6 in the presence of 1% FBS ( Fig. 2A) . Cationic liposomal delivery resulted in a 2-fold increase in ceramide accumulation by MDA cells, with a maximal accumulation observed at approximately 16 h. Conventional and pegylated liposomes were observed to have similar in vitro pharmacokinetic profiles (data not shown).
We next investigated the mechanism by which C 6 is released or transferred from liposomal vehicles into cellular membranes. We used a nontransferable cholesterol lipid marker, [
3 H]CHE, as a probe for liposome/cell membrane association. In these experiments, liposomes were tagged with either [
3 H]C 6 or [ 3 H]CHE and incubated with MDA cells for the indicated time periods. In Fig. 2B , it is evident that liposomes mediated the transfer of C 6 , but not cholesterol, from drug vehicle to cellular membrane. In fact, as C 6 accumulation increased over time, CHE accumulation failed to significantly increase above background levels. The disparity between ceramide and cholesterol accumulation is also observed in a dose-dependent manner (Fig. 2C) . These studies suggest that C 6 is delivered via lipid transfer processes that permit C 6 to partition out of the liposomal bilayer into the plasma membrane bilayer without associated liposome/cell membrane fusion.
Cell Proliferation. Several types of liposomal vehicles can be used for drug delivery. We initially investigated whether conventional lipid formulations would be useful for the delivery of short-chain ceramide to MDA cells. In Fig. 3A , a conventional liposome containing EPC and CH (solid lines) supplemented with C 6 displayed a significant dose-dependent inhibition of MDA cell proliferation. The addition of a vesicle-destabilizing lipid, DOPE, into a conventional formulation did not further enhance the bioactivity of C 6 . MDA cells, in the presence of 10% FBS for 12 h of treatment, were completely growth inhibited when treated with liposomal C 6 at 25 M or greater. The delivery of C 6 in liposomal formulations reduced the IC 50 approximately 3-fold, decreasing from 15 to 5 M, nonliposomal C 6 to liposomal C 6 , respectively. These conventional formulations displayed an improved dose-response inhibition of growth in MDA cells compared with nonliposomal administration of C 6 in DMSO vehicle (dashed line, open circle), indicating improved potency and efficacy. Liposomes without C 6 (Ghost; dashed line, open square) as well as PBS controls did not display significant growth inhibition, implicating C 6 as the only bioactive agent. This experiment demonstrates that C 6 -formulated conventional liposomes are more effective as an antiproliferative than freely administered C 6 .
We next investigated whether C 6 could also be efficacious when incorporated into cationic lipid formulations (Fig. 3B) . 3 H]C 6 , were subjected to extrusion to produce conventional liposomes as described. Mean Ϯ S.E., n ϭ 3 separate experiments. Lipid composition remains consistent following extrusion of lipid micelle solution to produce liposomal vesicles (C). Representative thin layer chromatograph of conventional liposomal formulations [EPC/DOPE/ CH/C 6 (3.5:3:2:1.5) and EPC/DOPE/CH/DHC 6 (3.5:3:2:1.5)] separated using a CHCL 3 /MeOH/ddH 2 O (60:25:5) solvent system. As expected, C 6 but not DHC 6 was stained with iodine due to the lack of the C 4 -5 double bond of DHC 6 . . This experiment indicates that cationic liposome formulations could also be used to deliver bioactive ceramide to dose dependently inhibit cell proliferation.
Novel Drug Delivery Systems for
In the next set of experiments, we tested the role of pegylated lipid to further enhance the bioactivity of C 6 . We chose PEG-C8 for the additional potential benefit of membrane destabilization and subsequent liposome/membrane fusion . Additionally, the inclusion of PEG-C8 has been observed to facilitate time-release properties of liposomal bilayers, with the added benefit of bioavailability extension. Pegylated liposomes (stealth) did not significantly effect MDA cell proliferation, demonstrating that PEG-C8 is biochemically inert. Yet, C 6 -incorporated pegylated liposomes were as effective at inhibiting proliferation as conventional at 10 and 25 M (Fig. 3C ). This study indicates that a pegylated liposomal formulation designed for systemic drug delivery is also an effective vehicle for C 6 -mediated inhibition of MDA cell proliferation. Similar results were also observed in two highly aggressive and metastatic murine adenocarcinoma cell lines, 410.4 and T41 (McEarchern et al., 2001; Kundu and Fulton, 2002 ) (data not shown), alluding to the potential applicability of liposomal C 6 delivery as an experimental therapeutic. Taken together, C 6 delivered in multiple liposomal formulations displays an improved dose-response inhibition of growth compared with nonliposomal C 6 , indicating improved potency and efficacy.
Induction of Apoptosis. We next investigated whether C 6 -dependent growth inhibition correlates with enhanced apoptosis in MDA cells. To confirm that C 6 delivery leads to MDA cell apoptosis, we initially performed TUNEL analysis, which stains cleaved DNA, a hallmark of cellular apoptosis (Fig. 4A) . TUNEL staining of cycling, serum-fed MDA cells treated with liposomal and nonliposomal C 6 demonstrated no DNA fragmentation at 8 h. Liposomal and nonliposomal C 6 treatment induced DNA fragmentation in a similar manner to the DNase-positive control. Staining of cleaved 3Ј-OH DNA was observed at 16 h of treatment, a time point consistent with the in vitro pharmacokinetic profile of C 6 delivery. No apoptosis was observed with the Ghost formulation.
To quantitate the C 6 -induced apoptosis, we performed annexin V staining of treated cycling MDA cells. Annexin V stains phosphatidylserine on the outer leaflet of apoptotic cells, another hallmark of apoptosis. Following a 24-h treatment, liposomal C 6 induced a significantly greater amount of annexin V staining compared with nonliposomal C 6 , whereas the Ghost formulation had no effect (Fig. 4B) . Additionally, cell cycle analysis utilizing propidium iodide-stained MDA cells demonstrated a significant increase in the G 2 /M population (untreated, 5.56 Ϯ 0.11; nonliposomal C 6 , 7.15 Ϯ 0.28; and liposomal C 6 , 10.71 Ϯ 0.84) and in subG o /G 1 cellular debris (untreated, 9.95 Ϯ 0.13; nonliposomal C 6 , 14.55 Ϯ 3.94; and liposomal C 6 , 18.22 Ϯ 1.07) following liposomal treatment compared with nonliposomal treatment. Liposomes formulated with the "inactive" analog, DHC 6 , had a marginal effect on the G 2 /M population (nonliposomal DHC 6 , 5.90 Ϯ 0.13 and liposomal DHC 6 , 6.80 Ϯ 0.16) and on subG o /G 1 cellular debris (nonliposomal DHC 6 , 7.94 Ϯ 0.40 and liposomal DHC 6 , 11.05 Ϯ 0.11). Together, these proliferative and apoptosis studies indicate that liposomal delivery Cell Signaling Analysis. As we have previously shown that cell-permeable ceramides inhibit the phosphorylation of Akt and extracellular signal-regulated kinase, in various cell types, to limit cell proliferation and/or survival (Bourbon et al., 2001 (Bourbon et al., , 2002 , we examined ceramide-regulated Akt signaling pathways in MDA cells treated with liposomal and nonliposomal C 6 formulations. Pegylated liposomal C 6 was more effective at reducing IGF-1-stimulated pAkt levels than was nonliposomal ceramide, whereas the Ghost formulation had no effect on pAkt levels (Fig. 5, A and B ). Liposomal DHC 6 displayed a marginal inhibition of IGF-1-stimulated Akt phosphorylation compared with nonliposomal DHC 6 . We selected 8 h of C 6 treatment, as this time point corresponds to near maximal accumulation of C 6 into MDA cells. These studies support the fact that liposomal C 6 induces cell growth inhibition and apoptosis through long-term inhibition of Akt signaling cascades.
As apoptosis is associated with the up-regulation of caspase activity, we assessed caspase-3/7 activity following treatment of MDA cells with pegylated liposomes. Cells that were treated with liposomal ceramide displayed significantly greater caspase-3/7 activity than cells treated with nonliposomal ceramide (Fig. 5C ). No significant change in caspase-3/7 activity was observed with Ghost treatments. Taken together, these results indicate that C 6 -formulated liposomes are more effective than nonliposomal administration of C 6 , resulting in significant inhibition of MDA cell proliferation and eventual apoptotic death.
Discussion
Although there are many effective reagents available to introduce transcriptionally active DNA and even functional peptides and proteins into viable cells, approaches to deliver bioactive lipids into living cells are not generally available. The delivery of bioactive sphingolipids and their intercalation into cells is impeded by their physical-chemical properties that render these lipids hydrophobic and cell impermeable. Short-chain ceramide analogs, such as C 6 , are used widely as experimental tools to improve cell permeability while mimicking the effect of long-chain physiological ceramide. However, C 6 is a lipid and thus extremely hydrophobic by nature, potentially causing it to precipitate as a fine lipid micelle suspension when added, in DMSO or ethanol vehicle, to cell media (Radin, 2001 ). In addition, although it is a more cell-permeable analog of long-chain physiological ceramide, C 6 retains two aliphatic chains, which limits its intercalation into plasma membranes. Moreover, the existence of circulating and intracellular ceramidase promotes the conversion of bioactive ceramide to inactive metabolites. Thus, to realize the therapeutic benefits of ceramide bioactivity, there is a need for improved delivery systems to assist with solubility, cell permeability, and protection from enzymatic degradation.
Nonliposomal organic solvent systems have been investigated to augment the delivery of ceramide to cells (Radin, 2001) . It has been proposed that a dodecane/ethanol solvent system, which is insoluble in culture media, precipitates out with the ceramide and forms very small droplets, or micelles, that fuse with the plasma membrane (Ji et al., 1995) . The use of such precipitating solvents may be limited by the variability in particle size and access to cellular membranes. Protein adjuvants, such as bovine serum albumin, may also assist in vitro ceramide delivery via nonspecific lipid/protein interactions but would not permit the efficient delivery of sufficient quantities of C 6 to systemic targets. For this reason, we investigated a novel approach to optimize the delivery of C 6 to cells utilizing a lipid-based carrier system that improves ceramide solubility, assists with cell permeability, and potentially protects against degradation.
Numerous studies have been conducted to demonstrate the physiological behavior of short-and long-chain ceramides in artificial phospholipid bilayers, or liposomes (Van Blitterswijk et al., 2003) . Examining these systems in equilibrium, long-chain ceramides have been shown to enhance the degree of lipid acyl chain order within the bilayers (Holopainen et al., 1997) , to separate into ceramide-rich lipid domains (Holopainen et al., 1998) , and to contribute to the destabilization of lamellar phases (Veiga et al., 1999) . These biophysical properties hinder long-chain ceramide exchange between lipid bilayers, thus limiting spontaneous transfer between bilayers (Simon et al., 1999) . In fact, even though we have successfully formulated C 16 -ceramide incorporated liposomes, their biological efficacy is limited by inefficient transfer of C 16 -ceramide between lipid bilayers (unpublished data). However, short-chain ceramide analogs have different partitioning and behavior characteristics in biomembranes from physiological ceramides (Venkataraman and Futerman, 2000; Van Blitterswijk et al., 2003) . Due to its amphilic nature, C 6 labeled with N-(4-nitrobenzo-2-oxa-1,3-diazole)aminocaproic acid has been observed to spontaneously transfer out of lipid membranes and undergo transbilayer movement into other membranes via undefined lipid transfer mechanisms (Pagano and Martin, 1988; Van Blitterswijk et al., 2003) . Additional studies have shown that short-chain analogs undergo similar transbilayer movement, with a correlation between lipid hydrophobicity (i.e., chain length) of the short-acyl chain of ceramide and the rate of transbilayer transfer (Bai and Pagano, 1997) . However, these studies have not been expanded to clinical correlates, such as induction of apoptosis in transformed cell lines.
We observed that liposomal delivery ameliorates the primary problems associated with C 6 delivery and efficacy, preventing the bioactive lipid from precipitating out of solution so that it can be delivered to cells more effectively. Utilizing [ 3 H]C 6 and [
3 H]CHE in the liposomal vehicles, we were able to determine the accumulation of ceramide into MDA cells in culture and to gain insights into the mechanism of drug delivery. In vitro pharmacokinetic results show that liposomal delivery leads to a significantly greater cellular accumulation of C 6 than nonliposomal delivery. Peak accumulation occurred between 8 and 16 h, corresponding with the onset of cellular apoptosis. Using a nontransferable marker ([ 3 H]CHE) for lipid association, we observed that an insignificant quantity of cholesterol lipid was transferred into MDA cells.
[ 3 H]CHE cannot transfer from one bilayer to another and thus cannot accumulate within a cell unless all liposome constituents are incorporated into the cell (i.e., via fusogenic processes). This observation supports the notion that C 6 delivery from liposomes occurs via spontaneous interbilayer/ lipid transfer from liposome to cell plasma membrane (Venkataraman and Futerman, 2000) . We propose that liposomal delivery of C 6 , from multiple formulations (i.e., conventional, cationic, and pegylated) facilitates spontaneous interbilayer transfer upon transient liposome/cell interactions, resulting in efficient delivery of C 6 to cellular membranes in vitro.
We validated the applicability and benefits of liposomal C 6 delivery by examining the efficacy and bioactivity of intracellularly delivered ceramide. Ceramide accumulation has been shown to inhibit proliferation and/or induce apoptosis through several potential signaling pathways (Birbes et al., 2002; Gulbins and Kolesnick, 2002) . The ability of ceramide to reduce pAkt levels suggests that C 6 inhibits the Akt survival pathway, contributing to the observed apoptotic cell death (Zhou et al., 1998) . Moreover, liposomal delivery leads to significantly more caspase activation and results in a greater induction in cellular apoptosis than nonliposomal C 6 . Critical observations that liposomal delivery results in greater ceramide accumulation, which is associated with improved Akt inhibition, caspase stimulation, growth diminution, and the induction of apoptosis, illustrate the advantages of liposomal delivery of this bioactive lipid. It is of interest jpet.aspetjournals.org that liposomal DHC 6 delivery is somewhat effective in limiting Akt phosphorylation and inducing apoptosis in MDA cells. This may support the notion that the presumed "inactivity" of DHC 6 may be a function of delivery and not bioactivity.
It is envisioned that liposomes may be applicable for both local and systemic delivery of therapeutic ceramide analogs. For example, our laboratory has demonstrated that the local and direct delivery of C 6 from ceramide-coated balloons of embolectomy catheters limits neointimal hyperplasia (restenosis) in rabbits after stretch injury (Charles et al., 2000) . The Hallenbeck laboratory has demonstrated that cell-permeable ceramide analogs, in DMSO vehicle, delivered both intracisternally and intravenously induced a neuroprotective effect in rats following focal cerebral ischemia (Furuya et al., 2001 ). The clinical potential for the packaged delivery of C 6 with additional therapeutic agents in liposomal vesicles is significant. Studies have shown that ceramide may act synergistically with chemotherapeutic agents, such as paclitaxel (Mehta et al., 2000) and fenretinide (Maurer et al., 2000) . Thus, delivery of chemotherapeutic agents in C 6 -formulated liposomes may further enhance apoptotic actions. Moreover, targeted immunoliposomes or stealth liposomes may also benefit from C 6 -ceramide incorporation. Nonetheless, the true benefits of liposomal ceramide delivery will be realized in ongoing and future in vivo studies aimed at assessing the efficacy of systemic delivery in rodent models of carcinogenesis or inflamed arteries.
Note Added in Proof. A recent article by Shabbits and Mayer has also demonstrated that ceramide-enriched liposomes enhanced cytotoxicity of a human breast cancer cell line [Shabbits JA and Mayer LD (2003) 
